Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (2)
P 2 (1)

Trial Status

Recruiting2
Not Yet Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07312292Phase 2RecruitingPrimary

Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

NCT07390838Phase 1RecruitingPrimary

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

NCT07260058Phase 1Not Yet Recruiting

Immune Cell Therapy for Advanced Solid Tumors

Showing all 3 trials

Research Network

Activity Timeline